ORASIS PHARMACEUTICALS EXPANDS ACCESS TO QLOSI™ WITH NEW STARTER PACKS FOR EYE CARE PROFESSIONALS, BOLSTERING COMMERICAL ROLLOUT

Orasis Pharmaceuticals, an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities, has announced the availability of Starter Packs of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% to broaden access for patients seeking a flexible option to manage their presbyopia and allow greater first-hand experience for eye care professionals (ECPs).

The availability of Qlosi Starter Packs marks the next phase of Qlosi's successful commercial expansion. Since launching in the U.S. in April 2025, Qlosi has achieved strong market adoption. Thousands of ECPs are prescribing, and refill rates have exceeded expectations, signaling an upward trend in patient adoption, with no serious adverse events reported since launch.

Read more.